This is a multi-center prospective, single-arm, non-randomized, pivotal study that will continue to access the feasibility of the Xeltis Bioabsorbable Pulmonary Valved Conduit in subjects requiring right ventricular outflow tract correction or reconstruction due to congenital heart malformations.
Heart Defect, Congenital
Enrolling by invitation
Patient requiring RVOT reconstruction, suitable for 16 mm,18 mm, 20 mm and 22 mm valved conduit.
Male or Female.
Age > 2 years and < 22 years.
Right Ventricular to Pulmonary Artery peak gradient > 35mm Hg or moderate or severe Pulmonary regurgitation (≥3+), or have both (except for the patients undergoing a Ross procedure)
The patient, and the patient's parent / legal representative where appropriate, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent by signing the approved informed consent form.
The patient, and the patient's parent / legal representative where appropriate, and the treating physician agree that the subject will return for all required post-procedure follow up visits and the subject will comply with clinical investigation plan required follow-up visits.
Need for or presence of prosthetic heart valve at other position.
Need for concomitant surgical procedures (non-cardiac).
Patients with previously implanted pacemaker (including defibrillators), or mechanical valves.
Active infection or requiring current antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics) or viral infection.
Leukopenia, defined as White Blood cell Count < than:
2-12 years: 5.0 ×103 /μL
12 years - Adult:
Male: 4.5×103 /μL
Female: 4.5 ×103 /μL
Acute or chronic anemia, defined as Hemoglobin < than:
2-12 years 11.5 g /dl
Male: 13 g /dl
Female 12 g /dl
Male: 13.5 g /dl
Female: 12 g /dl Patients can be transfused to meet eligibility criteria
Thrombocytopenia, defined as Platelet count < than:
150,000/mm3 Patients can be transfused to meet eligibility criteria
Severe chest wall deformity, which would preclude placement of the PV conduit.
Pulmonary hypertension (≥ half of systemic systolic pressure)
Right ventricular outflow tract aneurysm.
Known hypersensitivity to anticoagulants and antiplatelet drugs and to the device materials. .
Immunocompromised patient defined as: autoimmune disease, patients receiving immunosuppressant drugs or immune stimulant drugs.
Subject has chronic inflammatory / autoimmune disease.
Need for emergency cardiac or vascular surgery or intervention.
Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that has a life expectancy of less than one year.
Currently participating, or participated within the last 30 days, in an investigational drug or device study.
Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months.
Females who are sexually active and are not willing to use adequate contraceptive precautions for the next 2 years
Subject has medical, social or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance.
Xeltis Bioabsorbable Pulmonary Valved Conduit
January 6, 2022
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: